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Abstract
Background: Coronary artery disease (CAD) remains the single most important cause of mortality worldwide. Many
candidate and GWAS genetic variants have been identified in the recent years. In the current study, we selected six SNPs
from various genes that have originally been identified in GWAS studies and examined the association of
SNPs individually and as a genetic risk score (GRS) with CAD and blood lipid levels in the Pakistani subjects.
Methods: Six hundred twenty-four (404 cases and 219 controls) subjects were genotyped for variants rs10757274 in
CDKN2A gene, rs17465637 in MIA3 gene, rs7025486 in DAB2IP gene, rs17228212 in SMAD3 gene, rs981887 in MRAS
gene and rs1746048 in CXCL12 gene, by TaqMan and KASPar allele discrimination techniques. Serum lipid parameters
were measured using commercially available kits. Statistical analyses were done using SPSS version 22.
Results: Individually, the single SNPs were not associated with CAD (p < 0.05). However, the combined GRS of 6 SNPs
was significantly higher in cases than controls (4.89 ± 0.11 vs 4.58 ± 0.08, p = 0.024). Among blood lipids, GRS showed
significant positive association with serum triglycerides levels (p = 0.022).
Conclusion: The GRS was quantitatively associated with CAD risk and showed association with serum triglycerides
levels, suggesting that the mechanism of these variants is likely to be in part at least through creating an atherogenic
lipid profile in subjects carrying high numbers of risk alleles.
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Background
Coronary artery disease (CAD) is a multifactorial chronic
disorder of coronary arteries progressing silently and usu-
ally has established to an advance stage by the time symp-
toms start appearing [1]. In CAD, a fatty material known as
plaque deposits inside the coronary arteries which narrows
their lumen and restricts flow of blood to myocardial mus-
cles, the process is known as atherosclerosis. Although born
with clear coronary arteries having wide lumen, the first
streaks of fatty material may appear in the teenagers [2] but
the disease is asymptomatic until the plaque has grown
enough to compromise the flow of blood [3]. Pakistan is a
developing South Asian country with a total population of
184.35 million in 2012–13 and is the 6th most populated
country of the world [4]. The major part of the population
(67.5%) lives in rural areas which has been estimated to
bear the greatest burden of heart disease due to lack of
awareness and unavailability of medical facilities [5]. The
prevalence of CAD is even high in Pakistan [6] with over
30% of the population (> 45 years of age) being affected by
the disease [7]. The disease burden has almost doubled in
urban Karachi since 1970 [8]. Punjab is the largest province
of Pakistan in terms of population accounting for more
than 45% of the entire population [9]. However, there is a
paucity of data on the estimates of risk factor of CAD or of
its control status in Punjab, Pakistan [10]. According to
latest WHO reports, cardiovascular diseases (CVD) are
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among the biggest non-communicable killers in Pakistan
and CAD represents a major type of CVD (http://www.
who.int/countries/pak/en/).
Both genetic and environmental factors contribute to
the development of disease. These conventional risk
factors (CRF) for the development of CAD can be classi-
fied into non-modifiable and modifiable categories. The
non-modifiable risk factors are older age, male gender
and having a family history of CAD. Modifiable CAD
risk factors include hypertension, diabetes, blood lipid
levels, obesity, smoking, unhealthy use of alcohol, seden-
tary life style and psychosocial stress [7, 11]. The non-
modifiable factors are innate and cannot be changed
whereas; modifiable risk factors can be changed through
life style/behavioural changes or drug interventions.
The plasma biomarkers of lipid metabolism, throm-
bosis, inflammation and metabolic status are important
components of CAD risk analysis. Blood lipid levels,
coagulation profile, C-reactive proteins, fibrinogen and
LP(a) levels were the biomarkers which had been in use
for CAD risk stratification [12]. Genetic determinants of
CAD risk analysis mostly included the genes regulating
these biomarkers. Compared to candidate gene studies
which target a gene known to have some role in cardiac
physiology, GWAS simultaneously target hundreds of
variants. Since this is not a hypothesis driven approach,
it is considered to be more unbiased and has the potential
to reveal new genetic associations with CAD [13, 14]. The
CAD associated SNPs identified from GWAS are mostly
intergenic and were unlikely to be explored by candidate
gene studies. However, because the effect size associated
with each variant is modest and generally common
variants have low effect size, it leaves much of the CAD
heritability unexplained [13].
In this study, we have included 6 GWAS SNPs and
aimed to investigate the biochemical and genetic risk
factors of CAD in the Pakistani people. The SNPs
included (with nearest annotated gene) were rs10747275
(in cyclin dependent kinase inhibitor 2A gene, CDKN2A)
[15], rs17465637 (in Melanoma inhibitory activity pro-
tein 3 gene, MIA3) [15], rs7025486 (in Disabled homolog
2-interacting protein gene, DAB2IP) [16], rs17228212 (in
Mothers against decapentaplegic homolog 3 gene, SMAD3)
[17], rs9818870 (in muscle RAS oncogene homolog gene,
MRAS) [18] and rs1746048 (in C-X-C motif chemokine
ligand 12 gene, CXCL12) [17]. These SNPs were selected
for analysis in Pakistani subjects because 1) Pakistani popu-
lation represents a unique ethnic group which allows the
study of concentrated risk genetic markers 2) the
selected SNPs have been reported to modulate serum
lipids in Caucasians therefore their analysis in Pakistan
can provide the information on the relationship of these
genetic variants with lipids and 3) these SNPs have not
been previously investigated in the Pakistani population
and the current study is the first report of their study in
our population. The biochemical risk factors included
were lipid profile parameters namely total cholesterol
(TC), very low density lipoprotein (VLDL), LDL-C, high
density lipoprotein cholesterol (HDL-C) and triglyceride
(TG) levels.
Methods
The analyses were carried out in a case-control study
design. The study was done at the Department of
Microbiology and Molecular Genetics, University of
the Punjab and Center for Cardiovascular Genetics,
University College London. A total of 623 subjects (404
diagnosed CAD cases and 219 healthy controls) were re-
cruited. The criteria for the selection of study subjects has
been described in detail previously [19]. The CAD patients
were selected from tertiary care hospitals of the province
of Punjab, Pakistan. These were diagnosed cases based
upon the ECG, cardiac echo, radiologic and troponin T/I
levels. Only those CAD cases were selected which were
recently diagnosed and had not started lipid lowering or
antihypertensive drugs therapy. The controls were appar-
ently healthy subjects, not having any history of an early
CAD in their family. It was taken care that cases and con-
trols represented all the socioeconomic groups. Subjects
with obesity (BMI > 26Kg/m2 for Asian populations [20])
were excluded from the study to reduce the possible
confouders. Any subject with infection was excluded
from the study. All participants gave a written informed
consent. The study was approved by the ethics committee,
University of the Punjab, Lahore and all the procedures
were in compliance with the Helsinki Declaration.
Genotyping
The DNA was extracted from whole blood leucocytes
using Wizard genomic DNA purification Kit (Promega,
USA) and were quantified using nanodrop (ND-8000,
USA). The genotyping was carried out in especially
designed 384 well plates (Micro Amp). All the six SNPs
were genotyped by KASPar allele discrimination tech-
nique according to the method given in section 2.22. For
all the SNPs, homozygous and heterozygous genotypes
were not properly separated after the standard KASPar
cycle. Three extra cycles were given to the plates after
which the genotypes were properly clustered. The geno-
types were also randomly confirmed by direct DNA
sequencing. After amplification, the results were analyzed
on the ABI Prism 7900HT (Applied Biosystems/Life
Technologies) and the genotypes were called using
sequence detection software (SDS), version 2.0. The
quality check of genotyping techniques was maintained
by the inclusion of non-template controls (NTCs).
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Statistical analysis
The results were analyzed using statistical package for
social sciences (SPSS) IBM, version 22. The continuous
variables like blood lipid levels were compared between
cases and controls using independent sample student t
test. Hardy Weinberg equilibrium was accessed by a χ2
goodness of fit test. The categorical variables such as
risk allele frequencies (RAFs) were compared between
cases and controls using χ2 test. Since CAD is a binary
variable, the association of the SNPs with CAD was
examined using binary logistic regression. The effect of a
range of risk alleles was calculated by GRS quartiles
selecting the lowest through highest GRS levels. Blood
lipid levels across different number of risk allele in GRS
were calculated by one way analysis of variance (ANOVA)
by selecting lipids as dependent variable and genescore as
the factor affecting lipids. The effect size/β effect which is
per risk allele effect of GRS on lipid levels (increase/
decrease) was calculated by running a linear regression
model (age and gender adjusted). As four SNPs were
simultaneously analyzed, a corrected p-value (0.05/4 =
0.01) was used as a significance cutoff.
Constructing a GRS
The GRS was calculated by adding the number of risk
alleles at all the loci included in the study. The risk alleles
were assumed to be acting in additive manner, i.e., each
risk allele had an equal contribution to the outcome and
each risk allele was coded as 1. So the protective homozy-
gous genotype with no risk allele was coded 0, the hetero-
zygous individual carrying one risk and one normal allele
was coded as 1 and the risk homozygous individual having
both risk alleles was coded as 2. In this way the GRS of an
individual can range from 0 (no risk allele) to 12 (with all
the alleles being risk alleles for 6 loci).
Results
The basic features of the SNPs, including chromosomal
location and the nearest annotated gene are presented in
Additional file 1: Table S1. The call rate of all the SNPs
was > 95% and all were in Hardy Weinberg equilibrium
collectively as well as in cases and controls separately
(p > 0.05). The selected SNPs were not in linkage disequi-
librium as tested by the pairwise LD calculator available at
http://archive.broadinstitute.org/mpg/snap/ldsearchpw.php.
The study power assuming a standard deviation of 1 and
with a sample size of 623 was 81%.
The risk allele frequencies in cases and controls are
given in Table 1. The RAFs were higher in cases compared
to controls, but the difference was not statistically signifi-
cant (p > 0.05). The number and percentage of individual
genotypes (common homozygotes, heterozygotes and risk
homozygotes) were calculated. The percentage of the risk
homozygotes was higher in cases than controls (Table 2).
The per allele CAD odds ratios of SNPs with confidence
intervals and significance levels is shown in Table 3. None
of the SNPs was found to be significantly associated with
CAD in the studied samples.
Whether there was an association between any of the
SNPs and lipid traits, including LDL-C, HDL-C, TC and
TG levels was also determined. As expected for these
GWAS SNPs, no significant association of any SNP was
observed with any of the lipid traits examined. For all the
SNPs, per allele beta estimates for association with lipid
Table 1 Comparison of risk allele frequencies between cases
and controls
SNP RAFs
Alleles Risk allele Cases Controls *p Total
rs10757274 A/G G 0.505 0.463 0.162 0.490
rs17465637 C/A C 0.651 0.621 0.292 0.640
rs7025486 G/A A 0.318 0.315 0.913 0.317
rs17228212 T/C C 0.207 0.176 0.190 0.196
rs9818870 C/T T 0.094 0.087 0.670 0.091
rs1746048 C/T C 0.675 0.630 0.114 0.659
RAF is risk allele frequencies *p is chi square p-value
Table 2 The genotypes of the SNPs
SNP/alleles CAD (404) Control (219)
rs10757274
AA 107 (26.5%) 60 (27.4%)
AG 186 (46.0%) 115(52.5%)
GG 111 (27.5%) 44 (20%)
rs17465637
AA 46 (11.4%) 31 (14.2%)
AC 190 (47%) 104 (47.5%)
CC 168 (41.6) 84 (38.4%)
rs7025486
GG 190 (47%) 99 (45.2%)
AG 171 (42.3%) 102 (46.6%)
AA 43 (10.6) 18 (8.2%)
rs17228212
TT 252 (62.4%) 151(68.9%)
CT 137 (33.9%) 59 (26.9%)
CC 15 (3.7%) 9 (4.1%)
rs9818870
CC 333 (82.4%) 184 (84%)
CT 66 (16.3%) 32 (14.6%)
TT 5 (1.2%) 3 (1.4%)
rs1746048
TT 40 (9.9%) 33 (15%)
CT 183 (45.3%) 96 (43.8%)
CC 181 (44.8) 90 (41.1%)
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traits were very low and statistically non-significant. The
only significant associations which were observed were
that of the SNP MIA3 rs17465637 with TG and CXCL12
rs1746048 with TC levels. The beta effect of each risk al-
lele ofMIA3 rs17465637 for TG was 10.2 ± 4.1 mg/dl (p =
0.01) and the beta effect of each risk allele of CXCL12
rs1746048 for TC was 6.5 ± 3.1 mg/dl (p = 0.04). The asso-
ciation of rs1746048 with TC, however, vanished at a
corrected p-value (0.01) (Table 4).
The genetic risk score constructed by adding the risk
allele count for each study subject was analyzed in rela-
tion to the CAD status. The mean GRS in cases was
higher in the cases than in the controls with a marginal
significance (4.89 ± 0.11 vs 4.58 ± 0.08, p = 0.024). The
bivariate regression analysis with CAD as a dependent
and GRS as an independent variable revealed a signifi-
cant association of GRS with CAD with an Odds ratio of
1.12 (CI: 1.01–1.24, p = 0.022). We divided the GRS into
quartiles and observed the highest frequency of the sub-
jects in the interquartile range. The mean values for lipid
parameters were checked across the quartiles and an
increase in the serum TG levels was observed in the top
quartile (p = 0.022). The β-effect to check the per risk
allele increase in the lipid parameters was quantified
using linear regression across the quartiles. The results
of these analyses are summarized in the Table 5.
Discussion
In this study, we have replicated the association of 6
SNPs with CAD in a group of Pakistani people. The
studied SNPs were GWAS hits for CAD in people of
European ancestry. Out of these 6 SNPs, 4 (rs10757274,
rs17465637, rs9818870 and rs1746048) were also con-
firmed in the recent CARDIoGRAMPlusC4D consortium
study [21]. All of these SNPs except DAB2IP rs7025486
were initial hits of Welcome trust case control (WTCCC)
and German MI studies [17].
In the current study, we could not find a statistically
significant difference in the between the CAD cases and
controls, therefore these SNPs cannot be considered as
independent risk factors of CAD in the studied population.
This might be a power issue as the GWAS SNPs have been
studied with thousands of samples. The ethnicity may also
be another factor as the LD patterns differ in different
ethnicities and genetic factors also interact with that of
the environmental factors.
In CDKN2A rs10757274, the proportion of heterozy-
gotes was higher in controls than cases (52.5% vs. 46.0%)
but the risk homozygotes were higher in cases than con-
trols (27.5% vs.20%). Whereas, this SNP is the most fre-
quently and consistently associated GWAS hit for CAD.
The SNP was strongly associated with CAD in a cohort of
Asian Indians [22]. The SNP also exhibited association
with T2DM which is a CAD risk factor [23]. The region
9p21 is overlapped by ANRIL which is a non-coding RNA
gene [24]. The elevated expression of ANRIL is reported
in vascular tissues, smooth tissues and monocytes and all
have role in atherogenesis [25]. The ANRIL gene is consid-
ered to modulate the expression of neighbouring genes
such as CDKN2A and CDKN2B. Its role is also reported
in plaque stability, thrombogenesis and vascular endothe-
lium remodelling [26]. The variants at the region 9p21
were associated with increased expression of the ANRIL
gene which in turn is proatherogenic [27]. So far the
CDKN2A rs10757274 has been reported to be associated
with CAD in many diverse ethnicities but it failed to
improve net reclassification index or discrimination of
CAD when considered along with other conventional
CAD risk factors [28].
The risk allele of MIA3 rs1746537 was not associated
with CAD but was increasing TG levels in our study.
The association with blood lipids had not been confirmed
in a previous study on about 25,000 individuals [29]. So
this SNP might be causing CAD by raising TG levels in
Pakistani population or it may be a chance finding or false
positivity due to multiple testing. The association of this
SNP with CAD has been reported in American Cauca-
sians [30]. Whereas the association remained inconsistent
in three follow up studies on Chinese people, however, a
subsequent meta-analysis on five Asian populations con-
firmed the association with CAD in this ethnic group [31].
The association with CAD without affecting plasma lipids
and other CAD biomarkers was also found in Japanese
population [32]. The SNPMIA3 rs17465637 was identified
as a possible CAD risk after combining the results from
WTCCC and German MI family study. The association
was reported to be about 8% which was the second stron-
gest association [17].
No association of DAB2IP rs7025486 with CAD or any
of the lipid traits was observed in our samples whereas;
a strong association of this SNP with CAD was reported
in a previous meta-analysis [16]. Loss of DAB2 interacting
protein due to gene methylation increases cell prolifera-
tion and decreases apoptosis in certain type of cancers.
The protein normally reduces cell proliferation and accel-
erates cell senescence and its direct role in cardiac func-
tioning has not been shown yet [33]. The SNP SMAD3
Table 3 Per allele CAD odds ratios of the studied SNPs
SNP OR 95% C.I Significance
rs10757274 1.18 0.93–1.5 p = 0.17
rs17465637 1.14 0.89–1.5 p = 0.29
rs7025486 1.01 0.79–1.3 p = 0.91
rs17228212 1.22 0.91–1.65 p = 0.19
rs9818870 1.09 0.73–1.62 p = 0.68
rs1746048 1.22 0.95–1.6 p = 0.12
OR is odds ratio, C.I is confidence interval
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rs17228212, as expected was not associated to any of the
lipid parameters studied. However, the SNP has been re-
ported to be associated with risk of cardiovascular disease
and a subclinical atherosclerosis [34]. The SNP MRAS
rs9818870 was also not found to be associated with CAD
and lipid parameters. However, the SNP has been
proved to be a predictor of cardiovascular disease risk
in CAD free individuals [35]. The minor allele frequency
of this SNP in Caucasians was significantly higher than
Chinese according to HAPMAP II [36]. The SNP CXCL12
rs1746048 was not associated with CAD; however the
minor allele was raising TG levels. This may be a new
finding observed in Pakistani people and need to be repli-
cated in this ethnic region. However, a strong association
of this SNP with CAD was observed in a large meta-
analysis and case control study on Han Chinese popula-
tion [37]. Similarly, the SNP was also associated with MI
in an additive manner in Chinese people [38].
In this study, the GRS was calculated assuming that all
the SNPs had an equal effect on the outcome and act
Table 5 Comparison of Mean lipid parameter values across GRS
quartiles
Parameter Q1 Q2 Q3 β-effect p-value
TC (mg/dL) 192.6 ± 4.3 197.2 ± 2.4 196.6 ± 3.3 0.049 0.676
TG (mg/dL) 160.2 ± 6.1 202.4 ± 3.2 212.4 ± 6.1 0.064 0.022
HDL-C (mg/dL) 53.8 ± 1.5 53.1 ± 1.8 48.3 ± 3.1 −0.064 0.536
LDL-C (mg/dL) 93.9 ± 2.7 93.6 ± 1.5 104.8 ± 1.3 0.020 0.449
Q1: GRS 0–4, Q2: GRS 5–8, Q3: GRS 9–12
Table 4 Association of the SNPs with lipid traits individually
SNP Genotype LDL-C HDL-C TC TG
rs10757274 AA 99.6 ± 28.2 53.4 ± 19 196.7 ± 52.3 205.4 ± 68.9
AG 97.3 ± 27 53.9 ± 17.4 195.2 ± 51.8 203.2 ± 71
GG 99.6 ± 27.1 50.8 ± 14.6 197.6 ± 54 203.4 ± 68.2
β(Se) 0.06 (1.52) 1.27 (0.96) 0.5 (2.9) 1.01 (3.9)
p-value 0.97 0.188 0.88 0.794
rs17465637 AA 96.3 ± 23 54.8 ± 18.1 190.7 ± 52.3 196.5 ± 68.8
AC 99.4 ± 26.8 53.6 ± 16.4 196.9 ± 52.0 206.6 ± 68.2
CC 98 ± 29.1 51.8 ± 17.9 197.1 ± 53 217.0 ± 76
β (se) 0.17 (1.6) 1.6 (1.0) 2.3 (3.1) 10.2 (4.1)
p-value 0.92 0.13 0.46 0.01
rs7025486 GG 98.3 ± 26.5 53.7 ± 17.0 195.4 ± 50.7 203 ± 70.7
AG 99.0 ± 28.0 52.9 ± 17.7 197.9 ± 54.1 206.7 ± 70.4
AA 96.8 ± 28.5 50.0 ± 16.0 192.5 ± 53.4 194.4 ± 61
β (Se) 0.19 (1.7) 1.5 (1.0) 0.07 (3.2) 1.3 (4.3)
p-value 0.91 0.16 0.98 0.76
rs17228212 TT 98.3 ± 25.5 53.1 ± 17.2 195.4 ± 52.8 204.5 ± 68.4
CT 99.2 ± 30.2 52.7 ± 17.8 198.3 ± 52.2 203.3 ± 71
CC 95.8 ± 33.3 53.1 ± 14.6 192.5 ± 50 195.6 ± 81
β (Se) 0.07 (2) 0.3 (1.2) 1.2 (3.7) 2.5 (5)
p-value 0.97 0.83 0.76 0.62
rs9818870 CC 97.7 ± 26.6 53.3 ± 17 196.8 ± 53.8 203.2 ± 68
CT 102.4 ± 29.6 52 ± 18.2 192.4 ± 43.7 203.3 ± 76.5
TT 102.9 ± 41.8 48.3 ± 17.7 206.6 ± 63.8 252.5 ± 74.0
β (Se) 4.1 (2.6) 1.6 (1.6) 1.9 (5) 6.7 (6.7)
p-value 0.11 0.35 0.7 0.32
rs1746048 TT 97.1 ± 28.2 53.5 ± 19.2 185.8 ± 50.3 205.1 ± 61.2
CT 100.4 ± 26.6 52.6 ± 16.9 195.1 ± 51 205.9 ± 72.9
CC 96.9 ± 27.8 53.3 ± 17.1 200.1 ± 54.1 201.3 ± 68.6
β (Se) 1.2 (1.6) 0.1 (1) 6.5 (3.1) 2.7 (4.2)
p-value 0.47 0.9 0.04 0.51
β (Se) is the effect size with standard error. Values are mentioned as mean ± SD. The analyses were adjusted for age and gender
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additively. However, this may not always be the case be-
cause the effect size of some SNPs is relatively high
while some have more modest effects. At the same time,
some SNPs may be positively correlated while others can
be negatively correlated with the outcome; we therefore
adjusted coding for all the SNPs such that they had same
direction of association with CAD. The GRS was also
significantly associated with CAD risk. However, the ef-
fect sizes of the SNPs may vary among ethnicities as
linkage disequilibrium and allele frequencies vary [39].
The study had the limitations of small sample size, inabil-
ity to include more biochemical parameters and inclusion
of only a certain number of SNPs. As none of the SNPs
showed significant association with the CAD individually,
these genetics markers could not independently explain risk
susceptibility to CAD. Thus, the genotype has to be consid-
ered in relation to the phenotype and clinical presentation
due to the multifactorial nature of CAD.
Conclusion
In conclusion, the studied samples were although within
Hardy Weinberg equilibrium, but a significant association
of risk alleles with CAD could not be proved, although
RAFs were always higher in CAD cases than controls.
However, the study replicated the findings that these
GWAS hits were not associated to the blood lipid traits as
in previous GWAS studies. It is thus useful to use a panel
of risk variants that can be used to construct a GRS which
provides advantages over the use of single SNPs.
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